CIC
HBIO icon

Cornercap Investment Counsel’s Harvard Bioscience HBIO Stock Holding History

Cornercap Investment Counsel’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,805
Closed -$418K – 634
2023
Q4 		$418K Hold
7,805
– – 0.07% 466
2023
Q3 		$336K Sell
7,805
-111
-1% -$5.12K 0.06% 461
2023
Q2 		$435K Buy
+7,916
New +$434K 0.08% 440

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cornercap Investment Counsel's HBIO Position: Q1 2024 in Review

Cornercap Investment Counsel sold out of Harvard Bioscience (HBIO) in Q1 2024, closing a stake of 7,805 shares — an estimated $418K sold.

Cornercap Investment Counsel first reported a position in HBIO in Q2 2023 and held it in 3 quarters. The position peaked at $435K in Q2 2023. 89 funds tracked by Wall St. Rank hold HBIO as of Q1 2024.

  • Cornercap Investment Counsel reported no remaining Harvard Bioscience position as of Q1 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 7,805 Harvard Bioscience shares in Q1 2024, an estimated $418K.
  • Cornercap Investment Counsel first reported a position in Harvard Bioscience in Q2 2023 and held it in 3 quarters.
  • Cornercap Investment Counsel's Harvard Bioscience position peaked at $435K in Q2 2023.
  • 89 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2024.

Based on Cornercap Investment Counsel's 13F filing for Q1 2024, filed 10 May 2024.